Soluble P-Selectin During a Single Hemodialysis Session in Patients With Chronic Renal Failure and Erythropoietin Treatment

2007 ◽  
Vol 13 (4) ◽  
pp. 410-415 ◽  
Author(s):  
Ján Staško ◽  
Peter Galajda ◽  
Jela Ivanková ◽  
Pavol Hollý ◽  
Eva Rozborilová ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Plasma Levels ◽  
Platelet Factor 4 ◽  
Control Group ◽  
Healthy Controls ◽  
Soluble Adhesion Molecules ◽  
Platelet Factor ◽  
Soluble P

In several studies, hemodialysis (HD) patients treated with recombinant human erythropoietin (rHuEPO) because of renal anemia showed increased levels of soluble adhesion molecules. The purpose of the study was to investigate the changes of soluble P-selectin (sSELP) and its relationship to platelet activation during a single HD session in patients with long-term rHuEPO treatment. Fifty-two HD patients with chronic renal failure were involved—26 with rHuEPO treatment (EPO group) and 26 without (non-EPO group). Thirty healthy subjects served as the control group. The sSELP, β-thromboglobulin, and platelet factor 4 plasma levels were measured before and after a single 4-hour HD session on a cuprophane dialyzer. The basal β-thromboglobulin and platelet factor 4 plasma levels were significantly increased in both HD groups compared with healthy controls but did not change after a single HD session, except for a significant decrease of platelet factor 4 in the non-EPO group. The predialysis sSELP plasma levels did not differ significantly compared with those of the healthy controls, but there was a significant increase of sSELP levels after a single HD session in both groups (EPO, P < .005; non-EPO, P < .05, respectively). These results suppose that the increased sSELP level was released from platelets during the course of a single HD session. The more significant increase of the sSELP plasma levels in EPO group during HD indicates that platelets are more activated in patients with long-term rHuEPO treatment, and this fact could partially explain the suspected tendency for thrombosis in these patients.

Plasma β-Thromboglobulin And Platelet Factor 4 In Patients With Chronic Renal Failure And Effect Of Hemodialysis

1981 ◽  
Author(s):  
Y Endo ◽  
M Mamiya ◽  
K Takahashi ◽  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Statistical Significance ◽  
Normal Subjects ◽  
Statistical Correlation ◽  
Platelet Factor 4 ◽  
Cellulose Membrane ◽  
Heparin Infusion ◽  
Platelet Factor ◽  
The Difference

We have reported that jS-thromboglobulin (β-TG) and platelet factor 4 (PF4) increased in chronic renal failure. The purpose of the current study is to reveal a correlation between plasma β-TG (Amersham Corp. England) and renal function, a correlation between plasma β-TG and PF. (Abbott Lab., USA) and the effect of hemodialysis on patients with chronic renal failure.Significantly increased levels of plasma β-TG (76.8±25.5 ng/ml, p<0.01) were observed in 24 patients with chronic renal failure (BUN>20mg/dl), compared to normal subjects (13.2±5.6ng/ml). The increase in β-TG was highly correlated with BUN (r=0.651, p<0.01), creatinine (r=0.778, p<0.01) and creatinine clearance (r=-0.723, p<0.01). Although plasma PF4 (normal 5.0±2.0ng/ml) increased also, no statistical significance could be found. Statistical correlation between β-TG and PF4 was not found in these patients. This reason is thought to Be due to the difference of molecular weight (PF. 8000MW, β-TG 36000MW) and half-life (PF4 30min,β-TG 100min) The high levels of β-TG (89.4±3.4ng/ml) showed a further increase (109.4±5.8ng/dl, p<0.01) after dialysis. This is thought to be due to hemoconcentration, because of no adhesion of platelet to cellulose membrane but about 20% elevation in mean of other blood factors such as RBC, WBC, platelet, fibrinogen etc. The PF4 levels (before, 7.7±1.3ng/ml) which increased at 15min (55.2±19.6ng/ml, p<0.01) and 1 hr (23.7±8.4ng/ml, p< 0.01) are thought to be due to the influence of heparin infusion. The change in PF4. was not accompanied by the change in β-TG. During hemodialysis the decrease of other platelet functions such as adhesiveness, aggregation induced by ADP, collagen and PF3remained unchanged.

Increased Levels of Low Affinity Platelet Factor 4 in Plasma and Urine of Patients With Chronic Renal Failure.

1979 ◽  
Author(s):  
S. Niewiarowski ◽  
J. Guzzo ◽  
A.K. Rao ◽  
I. Berman ◽  
P. James
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Platelet Rich Plasma ◽  
Secretory Protein ◽  
Platelet Factor 4 ◽  
Platelet Factor ◽  
Specific Radioimmunoassay ◽  
Normal Individuals ◽  
Group 2 ◽  
Group 1

Low affinity platelet factor 4 (LA-PF4) is a specific platelet secretory protein immunologically related to β-thromboglobulin and to platelet basic protein that stimulates cell growth. The level of LA-PF4 antigen was determined by specific radioimmunoassay in platelet poor plasma (PPP) and platelet rich plasma (PRP) of 17 normal individuals (NI), 9 patients on hemodialysis (HD) and 18 patients with chronic renal failure (CRF) who were not dialysed. Eight patients with glomerular filtration rate (GFR) 5-20 ml/min were included to group 1 and 10 patients with GFR 30-50 ml/min were included to group 2. Levels of LA-PF4 in ng/ml PPP were 31.9 ± 2.8 in NI, 291.8 ± 26.3 in HD, 149.4 ± 45.2 in group 1 of CRF and 103.7 ± 11.1 in group 2 of CRF. Differences between patients and NI were significant at P <0.05. After 3 hours of hemodialysis LA-PF4 increased to 505.0 ± 92.3 (P < 0.05), however, there was no changes in PPP level across the artifical kidney at one hour. The levels of LA-PF4 in PRP of patients with CRF and HD did not differ from NI. Mean LA-PF4 excretion in urine (ng/day/100mg creatinine) was 57.7 ± 6.4 (range 33.3-75.7) in 6 NI with GFR >60 ml/min and 1461.5 ± 674.6 (range 105.3-7041.6) in 10 CRF patients. In conclusion, elevation of LA-PF4 in PPP of patients with CRF and its increased urinary excretion suggest stimulation of platelet secretion and/or decreased metabolism of LA-PF4 in the kidney.

scholarly journals Long-Term Plasma Levels and Dose Modulation of Alacepril in Patients with Chronic Renal Failure

2008 ◽  
Vol 31 (1) ◽  
pp. 29-36 ◽  
Author(s):  
Hiroshi NONOGUCHI ◽  
Shigeru KIYAMA ◽  
Kenichiro KITAMURA ◽  
Masahiro NARUSE ◽  
Masao TOMITA ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Plasma Levels ◽  
Dose Modulation

scholarly journals Evaluation of plasma zinc and copper in patient with chronic renal failure in Khartoum State - Sudan

2019 ◽  
Vol 9 (2) ◽  
pp. 352-354
Author(s):  
Salman Taha Ahmed Elmukashfi ◽  
Abdelwahab Abdien Saeed ◽  
Mutaz Ibrahim Hassan
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Plasma Level ◽  
Plasma Levels ◽  
Test Group ◽  
Control Group ◽  
P Value ◽  
Main Function ◽  
Gender And Age ◽  
The Mean

The kidney is complex vital organs, and has many functions. The main function it‘s removal of toxic and excess  substancesfrom the plasma, if there is any defect in the kidney like renal failure can disrupt  this function. The aim of this study was to determine the level of Zinc and Copper in Sudanese patient with chronic renal failure. This study was designed as case control, which includes 100 blood samples, a 60 from these sample were collected from patient with chronic renal failure and 40 samples were collected from health individual as control group and the sample is collected by using sterile disposable syringes and separated by centrifuge. Carried out in Ribat University Hospital in Khartoum state, during period from March to June 2018. And the plasma levels of zinc and copper determined by the use of atomic absorption spectrophotometer (OPERATOR’S MANUAL January 2003 VER 3.94 C), and the obtained results were analyzed by SPSS. The result of this study showed that there was significant decrease (p<0.05) in the plasma levels of zinc and copper in patient with chronic renal failure compared to the control subjects. The mean of plasma Zn was 0.3mg/l in test group and 0.7mg/l in control group with p. value of 0.002 and the mean of plasma Copper was 0.5mg/l in test group and 0.7mg/l in control group with p. value of 0.019. Also the study showed the gender and age of the patient, also the duration of the disease have no effect on the plasma level of zinc and copper (p 0.05). The study concludes that the plasma level of zinc and copper are low in patient with chronic renal failure. And the gender and age of the patient also the duration of disease have no significant effect on the plasma level of zinc and copper. Keywords: Chronic Renal Failure, Zinc, Copper, Sudanese

scholarly journals Plasma lipopolysaccharide binding protein and bactericidal/permeability increasing factor in CRF and HD patients.

1996 ◽  
Vol 7 (3) ◽  
pp. 479-487
Author(s):  
B J Pereira ◽  
S Sundaram ◽  
B Snodgrass ◽  
P Hogan ◽  
A J King
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Plasma Levels ◽  
Cytokine Production ◽  
Binding Protein ◽  
Interleukin 1 ◽  
Healthy Controls ◽  
Lipopolysaccharide Binding Protein ◽  
Alpha Production ◽  
Lipopolysaccharide Binding

The recent characterization of lipopolysaccharide binding protein (LBP) and bactericidal/permeability increasing factor (BPI) have provided the opportunity to examine the natural factors that regulate cytokine production in response to endotoxin in patients on hemodialysis (HD). Whole blood was collected in EDTA from 28 undialyzed patients with chronic renal failure (undialyzed CRF), 36 patients on chronic HD (HD) and 15 healthy controls, and plasma levels of LBP and BPI were measured by a sandwich ELISA. Plasma LBP levels in undialyzed patients with CRF (P = 0.04) and patients on HD (P = 0.01) were significantly higher than those in healthy controls, but not significantly different from each other. Plasma BPI levels in undialyzed patients with CRF and patients on HD were not significantly different from those in healthy controls. There was no correlation between serum creatinine and plasma levels of either LBP or BPI. Peripheral blood mononuclear cells (PBMC) were harvested from healthy volunteers by FLcoll-Hypaque separation, and 0.125 mL of 10 x 10(6)/mL suspensions were incubated with 0.125 mL of test plasma (containing different LBP/BPI ratios) and 0.25 mL of RPMI, containing 1 ng/mL of endotoxin, for 24 h at 37 degrees C. Samples were subjected to three freeze-thaw cycles, and total interleukin-1 receptor antagonist (IL-1Ra) or interleukin-1 alpha (IL-1 alpha) production was measured by a specific non-crossreactive RIA. The results of this study showed: (1) IL-1Ra production by endotoxin-stimulated PBMC incubated with pooled plasma from HD patients with LBP/BPI ratios of 11 x 10(2), 167 x 10(2), 379 x 10(2), and 778 x 10(2), respectively was 1466 +/- 195 pg, 3105 +/- 462 pg, 8179 +/- 1020 pg, and 4770 +/- 1185 pg (P < 0.001); (2) Paired plasma collected before dialysis (predialysis) and at 15 min after the start of dialysis (15 minute) with cellulose membranes showed a negligible change in plasma LBP levels (-3 +/- 5%), but a 6681 +/- 1788% increase in plasma BPI levels. Consequently, compared with predialysis plasma, there was a 35 +/- 6% decrease in endotoxin-stimulated IL-1 alpha production by PBMC incubated with plasma drawn at 15 min (P = 0.001); (3) Compared with the PBMC incubated with predialysis plasma from HD patients, there was a 39 +/- 5%, 53 +/- 5%, and 60 +/- 5% decrease in endotoxin-stimulated IL-1 alpha production in the presence of 1 ng/ mL, 10 ng/mL, or 1 microgram/mL of recombinant BPI, respectively (P < 0.003). These results suggest that the plasma LBP:BPI ratio could influence cytokine production in response to bacterial endotoxin; the high LBP:BPI ratios observed in patients with chronic renal failure probably imparts an increased susceptibility to endotoxin-stimulated cytokine production; and natural or pharmacological increases in plasma BPI levels and the consequent decrease in LBP:BPI ratios could attenuate this susceptibility to endotoxin-stimulated cytokine production.

Plasma Ghrelin Levels in Children with Chronic Renal Failure on Peritoneal Dialysis

2007 ◽  
Vol 27 (1) ◽  
pp. 61-66 ◽  
Author(s):  
Maria Szczepańska ◽  
Krystyna Szprynger ◽  
Bogdan Mazur ◽  
Danuta Zwolińska ◽  
Katarzyna Kilis-Pstrusińska ◽  
...  
Keyword(s):  
Renal Failure ◽  
Peritoneal Dialysis ◽  
Chronic Renal Failure ◽  
Conservative Treatment ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Control Group ◽  
Healthy Children ◽  
Healthy Controls ◽  
Loss Of Appetite

Objectives Malnutrition and loss of appetite represent a serious problem in children with chronic renal failure. Ghrelin is a newly described hormone involved in control of growth hormone secretion, stimulation of food intake, and regulation of energy balance. Methods Plasma ghrelin levels were compared between 12 children on automated peritoneal dialysis (APD) and 9 children on conservative treatment of chronic renal failure. Eight healthy children matched for age and body mass index (BMI) served as a control group. Results Plasma ghrelin levels were similar in children on APD (698.3 ± 59.7 pg/mL) and children on conservative treatment (675.4 ± 41.9 pg/mL) compared to healthy controls (700.1 ± 24.7 pg/mL). There was no difference in plasma ghrelin levels in children with chronic renal failure regardless of the method of treatment (peritoneal dialysis vs conservative treatment). The plasma ghrelin index was similar in all three investigated groups: APD 40.2 ± 8.7 vs conservative treatment 39.1 ± 5.6 vs controls 41.0 ± 7.8 (pg/mL)/BMI (kg/m2). Plasma ghrelin levels did not correlate with age, duration of dialysis treatment, height, weight, BMI, creatinine and urea levels, adequacy parameters, or nightly glucose load. Conclusion Plasma ghrelin levels in children on APD were not different from levels in children on conservative treatment or healthy controls with comparable BMI. The persistent state of toxic influence of uremic end-products could be responsible for such a lack of correlation with anthropometrical parameters. Further studies on a larger group of children on APD are needed to clarify the effect of ghrelin on nutritional status in children with chronic renal failure.

scholarly journals Plasma .BETA.-thromboglobulin and platelet factor 4 in patients with chronic renal failure and effect of hemodialysis.

1981 ◽  
Vol 135 (4) ◽  
pp. 349-358 ◽  
Author(s):  
YASUYUKI ENDO ◽  
SHIGEO MAMIYA ◽  
MAKI SATOH ◽  
KEIKO TAKAHASHI ◽  
TADASHI HARADA
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Platelet Factor 4 ◽  
Platelet Factor

Platelet Aggregation, β-Thromboglobulin and Platelet Factor 4 in Diabetes Mellitus and in Patients with Vasculopathy

1984 ◽  
Vol 52 (03) ◽  
pp. 236-239 ◽  
Author(s):  
J Fritschi ◽  
M Christe ◽  
B Lämmle ◽  
G A Marbet ◽  
W Berger ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Platelet Aggregation ◽  
Discriminant Analysis ◽  
Plasma Levels ◽  
Platelet Activating Factor ◽  
Platelet Factor 4 ◽  
Platelet Factor ◽  
Aggregation Response ◽  
The Difference

SummaryWe have studied 155 subjects, 48 normals, 36 diabetics without complications, 44 with complications and 27 patients with macroangiopathy. β-Thromboglobulin (β-TG) and platelet factor 4 (PF4) are elevated in the patients groups. There is no correlation between the plasma levels of β-TG and the stages of either retinopathy or macroangiopathy or nephropathy. The difference is more marked between normals and diabetics with neuropathy (p = 0.026). The aggregation response to ADP and platelet activating factor (PAF) is enhanced at lower stimulator concentration. Using the β-TG, PF4 and aggregation values the discriminant analysis allows a distinction of several subgroups especially with nephropathy and neuropathy (Table 6).

Sign in / Sign up

Export Citation Format

Share Document